• August 2, 2021

Cigna dodges proposed class motion over prescription drug pricing

May 22, 2021

A federal choose tossed a proposed class motion lawsuit by hundreds of well being plans in opposition to Cigna Corp. on Thursday, saying beneficiaries have been counting on a “whack-a-mole” method for coordinating the disparate language throughout the totally different contracts.

The federal lawsuit, filed in Connecticut district courtroom, aimed to consolidate the claims of hundreds of nationwide well being plans operated beneath the Worker Retirement Revenue Safety Act, or ERISA, and which comprised some 500 million transactions, in accordance with the grievance. These well being plans alleged that Cigna schemed to overcharge their contributors for pharmaceuticals bought, typically by as a lot as 300%. The lawsuit claimed that when a given prescription drug prices lower than a affected person’s copayment quantity, the insurer “clawed again” the distinction by way of an inappropriate technique stored secret from sufferers. This typically precipitated insured sufferers to pay extra for medicine than they’d with out insurance coverage, with pharmacists contractually prohibited from telling sufferers this info, in accordance with the go well with.

Cigna didn’t dispute this cost. The insurer argued that well being plans are complaining that their contracts didn’t supply them a pass-through pricing association, which requires pharmacy profit managers to cost payers the identical quantity that they reimburse pharmacies, together with a set administrative payment.

No matter which mannequin well being plans had agreed to, there have been too many variations within the authorized language to permit for decision on a classwide foundation, U.S. District Choose Jeffrey Alker Meyer wrote in his choice. Whereas plan contributors argued that these variations are usually not important, “how ought to I decide which phrases are particular and actual, and which phrases are normal?” Meyer wrote.

“This type of whack-a-mole method to what seem like materials variations just isn’t tenable,” he wrote. “Nor can I merely take plaintiffs’ phrase that different variations don’t exist in all the opposite hundreds of plans that fall beneath the category and subclass definitions. So far as I can inform, it’s holes with moles all the best way down.”

Whereas the choose denied plaintiffs’ class standing, he mentioned the well being plans had a proper to dispute claims going ahead, and that their skilled witness was dependable. Cigna had argued that, as a result of the witness was unable to incorporate particular person members’ deductibles when calculating how a lot its pharmacy profit supervisor profited from each transaction, his calculations weren’t an sufficient illustration of what the Bloomfield, Conn.-based insurer may owe every participant. Meyer wrote that he wasn’t there to evaluate the skilled witness’ technique for calculating the insurer’s alleged money owed; he was there to determine whether or not the person could possibly be trusted.

“I’m not all that involved that [the witness’s] methodology is at odds with Cigna’s concept of alleged legal responsibility,” he wrote.

Alker Meyer additionally dominated that Cigna may embody info from its doc supply device as proof, if it selected to, going ahead. Cigna didn’t reply to an interview request.

The ruling comes as authorities officers more and more examine their pharmacy profit managers. Whereas lots of the evaluations come from states like Arkansas, New Mexico and Mississippi which are investigating claims of inflated drug prices amongst their Medicaid managed-care applications, some officers are additionally investigating the pharmacy profit managers that handle their ERISA applications, in accordance with The Wall Avenue Journal.

Cigna at present faces a go well with from the Ohio Legal professional Common, alleging its Categorical Scripts pharmacy profit supervisor overcharged the state’s Freeway Patrol Retirement System for medicines.

Source link